Lloyd Smyth

“Clinical trials are vital because they’re driven by our doctors, who deeply understand our patients’ needs”

About Lloyd Smyth

What started as a simple spark of passion for science, healthcare, and improving lives has flourished into a remarkable career in radiation therapy and research for Lloyd Smyth.

Today, as Icon’s Investigator Initiated Trials Operations Manager at Icon Group (Icon), Lloyd plays a pivotal role in advancing patient care – expanding our Investigator Initiated Trials (IIT)* program – driven by the same goal since day one: to enhance patient outcomes.

Keep reading to discover more about Lloyd’s career and the impact he continues to make.

Curating a research career

Lloyd’s career began as a radiation therapist at Epworth Hospital, drawn to the blend of cutting-edge technology and direct patient care in a fast-paced, ever-evolving field.

Early in his career, Lloyd found himself involved in research—experiences that proved pivotal, making him realise he could do more than treat —he could shape the future of cancer care.

“Those early opportunities to engage in seemingly small projects made me realise I could build upon my skills as a radiation therapist and push the boundaries of cancer care through research,” Lloyd shared.

“I was fascinated by the idea of discovering new ways to improve cancer treatment— finding solutions where current treatments have reached their limit. That curiosity drove me to pursue research.”

Lloyd went on to complete his PhD and post-graduate fellowship away from the clinic looking at experimental forms of radiation therapy — FLASH and microbeam radiotherapy — before transitioning back into clinical research at Icon, where he continues to expand our research portfolio.

Transitioning from radiation therapist to researcher

Lloyd feels his background as a radiation therapist was essential to his success in research, particularly at Icon.

“Radiation therapists are known for being detail-oriented, process-driven, and always seeking more efficient ways to improve care,” Lloyd explained.

“These skills and past experiences in the clinic, have been invaluable, helping me collaborate effectively with doctors and researchers to find the best solutions for patients.”

While Lloyd’s clinical skills laid the foundation for his research career, he credits his time back in the academic world for accelerating his growth and crystalising his passion for clinical research.

“My research program pushed me to think differently, allowing me to collaborate with diverse stakeholders and think creatively to push the boundaries for cancer treatment and patient care,” Lloyd added.

Helping create impact, at scale

Lloyd plays a pivotal role in advancing Icon’s IITs and clinical research programs.

“My focus is on enhancing patient outcomes through research, helping transform novel ideas into trials that generate evidence to improve patient care,” Lloyd explained.

As our IIT Operations Manager Lloyd collaborates closely with our clinicians and staff, forging partnerships with industry leaders and sponsors to provide the necessary financial and intellectual support for our projects.

“While challenges often arise working in research, working with others who are dedicated to making a difference and seeing groundbreaking new treatments yield great results is incredibly rewarding,” Lloyd said.

The future of healthcare at Icon

Expanding access to IITs is a key priority at Icon, and funding is essential in making this possible.

“IITs are vital because they’re driven by our doctors, who deeply understand our patients’ needs,” Lloyd explained.

“These trials tackle the impactful questions, helping improve patient outcomes, and address areas of unmet clinical need, all while bringing research closer to home for those who might not otherwise have access.

“The Icon Cancer Foundation plays a crucial role in supporting these efforts, helping provide essential funding to bring more IITs to Icon and our patients.”

A pipeline for hope

Lloyd sees growth ahead for Icon’s research program.

“We have more projects in the pipeline, including brain, prostate, breast cancer, and melanoma trials – helping us build a high-quality program,” Lloyd said.

“With more industry partnerships and funding via the Icon Cancer Foundation, we hope to activate these within six to 12 months.”

Beyond cancer, Lloyd said our trials are exploring innovative uses of radiation to treat benign and degenerative conditions.

“Our technology has potential far beyond cancer, offering new hope for patients with chronic conditions and I can’t wait to see the benefit this brings more patients.”

Learn more:

Search

Quick links
Donate